StockNews.com Initiates Coverage on Harvard Bioscience (NASDAQ:HBIO)

StockNews.com initiated coverage on shares of Harvard Bioscience (NASDAQ:HBIO) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

Several other equities research analysts have also recently commented on HBIO. KeyCorp reiterated a “sector weight” rating on shares of Harvard Bioscience in a research report on Wednesday, April 9th. Benchmark reduced their price target on shares of Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a research report on Monday, March 24th.

Harvard Bioscience Stock Down 0.5 %

Shares of NASDAQ:HBIO opened at $0.39 on Friday. Harvard Bioscience has a 12 month low of $0.36 and a 12 month high of $4.08. The company’s 50-day moving average price is $0.71 and its two-hundred day moving average price is $1.65. The firm has a market cap of $17.10 million, a P/E ratio of -1.18 and a beta of 1.47. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Focus Partners Wealth bought a new stake in Harvard Bioscience in the 4th quarter valued at approximately $28,000. Intech Investment Management LLC acquired a new position in Harvard Bioscience during the fourth quarter worth $35,000. Sei Investments Co. bought a new position in Harvard Bioscience in the fourth quarter valued at $47,000. JPMorgan Chase & Co. increased its stake in Harvard Bioscience by 63.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock valued at $79,000 after buying an additional 11,397 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in Harvard Bioscience by 55.5% in the 4th quarter. Jane Street Group LLC now owns 35,769 shares of the medical instruments supplier’s stock valued at $75,000 after buying an additional 12,767 shares during the last quarter. 80.87% of the stock is currently owned by institutional investors.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.